Latest news Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development June 24, 2022 Diaccurate appoints Laurence Riot Lamotte as Chief Financial Officer February 8, 2022 Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany September 8, 2021 See all press releases Home Media Selected media Diaccurate Adds Merck PAM Inhibitor to Oncology/Immunology Pipeline September 9, 2021 Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway September 8, 2021 Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out August 12, 2021 Media contact details MC Services (US & EU) Anne Hennecke +49 211 529252 22 Simone Neeten +49 211 52925217 diaccurate@mc-services.eu ATCG Partners (France) Marie Puvieux +33 (0)9 52 78 85 08 diaccurate@atcg-partners.com
Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development June 24, 2022
Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany September 8, 2021
Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway September 8, 2021
Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out August 12, 2021
